Overview

Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Prospective observational study to IDEntify patients with advanced/metastatic NSCLC and ALK and ROS1 translocation and to establish their therapeutic management (IDEALK&ROS)
Details
Lead Sponsor:
Pfizer
Treatments:
Crizotinib